Research programme: asthma and COPD therapy - GlaxoSmithKline

Drug Profile

Research programme: asthma and COPD therapy - GlaxoSmithKline

Alternative Names: I-kappa-B kinase inhibitors research programme - GlaxoSmithKline; IKK-2 inhibitors research programme - GlaxoSmithKline

Latest Information Update: 17 Jan 2008

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Small molecules
  • Mechanism of Action NF-kappa B inhibitors; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 21 Jun 2005 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (unspecified route)
  • 21 Jun 2005 Preclinical trials in Chronic obstructive pulmonary disease in USA (unspecified route)
  • 21 Jun 2005 Data presented at the 101st International Conference of the American Thoracic Society (ATS-2005) have been added to the Respiratory Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top